Nicholas Robert, MD: Oncologists' Comfort Level With Biosimilars

Nicholas Robert, MD, medical director of data, evidence and insights at McKesson Life Sciences, discusses how comfortable oncologists are with using biosimilars.
October 01, 2019


So in terms of adoption, anything new faces some resistance. It depends on the impact. In conversation with my physician colleagues, supportive care is less of a hill to climb over, so to speak. When you start replacing drugs that have impact on therapeutic outcomes, physicians are cautious. I think people will be cautious. But I think the data to date certainly supports that there is certainly reason to adopt biosimilars in the therapeutic realm, so I suspect it’s going to happen. To be frank, there is an economic piece as well. If it’s a more attractive option, I think everyone is aware about the cost of healthcare, and certainly people think that biosimilars are one way to attack that problem. And I think, frankly, everyone involved is onboard to reduce healthcare costs.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.